Like many breast cancers, these cells also exhibit activation of the STAT3 signaling pathway (9, 10), which led us to explore the effects of romidepsin in comparison to and in combination with the STAT3 inhibitor Stattic. Here, STAT3 is linked to breast carcinoma.